Multi-layered nanoparticles for combination gene and drug delivery to tumors

Biomaterials

Volumn 35, Issue 34, 2014, Pages 9343-9354

  Ediriwickrema, Asiri ^a   Zhou, Jiangbing ^a,b   Deng, Yang ^a   Saltzman, W Mark ^a  

^a Yale University   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug delivery; Gene therapy; Nanoparticle; PLGA

Indexed keywords

CELL CULTURE; CELL DEATH; CHEMOTHERAPY; COPOLYMERS; DISEASES; DRUG DELIVERY; FUNCTIONAL POLYMERS; GENE THERAPY; GENE TRANSFER; GENES; LIPOSOMES; MERGERS AND ACQUISITIONS; NANOPARTICLES; TUMORS; SYNTHESIS (CHEMICAL);

CANCER CHEMOTHERAPY; CANCER THERAPEUTICS; COMBINATION THERAPY; FUNCTIONAL PEPTIDES; PLGA; POLY LACTIC-CO-GLYCOLIC ACID; POLYMER NANOCARRIERS; POLYMER NANOPARTICLES; SYNERGISTIC ACTION;

SYNTHESIS (CHEMICAL); DRUG THERAPY;

CAMPTOTHECIN; MULTILAYERED NANOPARTICLE; NANOPARTICLE; PEPTIDE DERIVATIVE; POLYETHYLENEIMINE; POLYGLACTIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; COUMARIN 6; COUMARIN DERIVATIVE; LIPOFECTAMINE; MULTILAYERED POLYMER NANOPARTICLE; NANOCARRIER; PEPTIDE; PLASMID DNA; POLYMER; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CHEMICAL COMPOSITION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG POTENTIATION; DRUG RELEASE; DRUG SYNTHESIS; DRUG TARGETING; GENE PRODUCT; GENETIC TRANSFECTION; HCT116 CELL LINE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER SIZE; CELL VIABILITY; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; DOSE RESPONSE; FLOW CYTOMETRY; GLIOBLASTOMA; GROWTH INHIBITION; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CANCER; NANOENCAPSULATION; NANOFABRICATION; NICK END LABELING; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; SINGLE DRUG DOSE; SURFACE PROPERTY; THERAPY EFFECT; TUMOR GROWTH; TUMOR XENOGRAFT; CHEMISTRY; GENE TRANSFER; GENETICS; HEK293 CELL LINE; METABOLISM; NEOPLASMS; PROCEDURES; TUMOR CELL LINE;

CAMPTOTHECIN; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HCT116 CELLS; HEK293 CELLS; HUMANS; LACTIC ACID; NANOPARTICLES; NEOPLASMS; PLASMIDS; POLYETHYLENEIMINE; POLYGLYCOLIC ACID; POLYMERS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION;

EID: 84906789102     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.07.043     Document Type: Article

References (45)

1. Cancer Facts and Figures 2013 2013, American Cancer Society, Atlanta.
2. De Vita V.T., Young R.C., Canellos G.P. Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer 1975, 35:98-110.
3. Hanahan D., Weinberg Robert A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
4. Kay M.A. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 2011, 12:316-328.
5. Fahmy T.M., Fong P.M., Goyal A., Saltzman W.M. Targeted for drug delivery. Mater Today 2005, 8:18-26.
6. Pirollo K.F., Chang E.H. Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res 2008, 68:1247-1250.
7. Zhou J., Liu J., Cheng C.J., Patel T.R., Weller C.E., Piepmeier J.M., et al. Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery. Nat Mater 2011, 11:82-90.
8. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012, 63:185-198.
9. Shea L.D., Smiley E., Bonadio J., Mooney D.J. DNA delivery from polymer matrices for tissue engineering. Nat Biotechnol 1999, 17:551-554.
10. Luo D., Woodrow-Mumford K., Belcheva N., Saltzman W.M. Controlled DNA delivery systems. Pharm Res 1999, 16:1300-1308.
11. Zhou J., Patel T.R., Fu M., Bertram J.P., Saltzman W.M. Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials 2011, 33:583-591.
12. Blum J.S., Saltzman W.M. High loading efficiency and tunable release of plasmid DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-L-lysine. JControl Release 2008, 129:66-72.
13. Son S., Kim W.J. Biodegradable nanoparticles modified by branched polyethylenimine for plasmid DNA delivery. Biomaterials 2010, 31:133-143.
14. Fields R.J., Cheng C.J., Quijano E., Weller C., Kristofik N., Duong N., et al. Surface modified poly(beta amino ester)-containing nanoparticles for plasmid DNA delivery. JControl Release 2012, 164:41-48.
15. Herbst R.S., Eckhardt S.G., Kurzrock R., Ebbinghaus S., O'Dwyer P.J., Gordon M.S., et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. JClin Oncol 2010, 28:2839-2846.
16. Ciusani E., Croci D., Gelati M., Calatozzolo C., Sciacca F., Fumagalli L., et al. Invitro effects of topotecan and ionizing radiation on TRAIL/po2L-mediated apoptosis in malignant glioma. JNO 2005, 71:19-25.
17. Singh T.R., Shankar S., Chen X., Asim M., Srivastava R.K. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma invivo. Cancer Res 2003, 63:5390-5400.
18. Xiang H., Fox J.A., Totpal K., Aikawa M., Dupree K., Sinicropi D., et al. Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors. Oncogene 2002, 21:3611-3619.
19. Rothenberg M.L. Topoisomerase I inhibitors: review and update. Ann Oncol 1997, 8:837-855.
20. Ertl B., Platzer P., Wirth M., Gabor F. Poly(D,L-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin. JControl Release 1999, 61:305-317.
21. Liu J., Jiang Z., Zhang S., Saltzman W.M. Poly(omega-pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery. Biomaterials 2009, 30:5707-5719.
22. Kelley S.K., Harris L.A., Xie D., DeForge L., Totpal K., Bussiere J., et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of invivo efficacy, pharmacokinetics, and safety. JPharmacol Exp Ther 2001, 299:31-38.
23. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. JClin Invest 1999, 104:155-162.
24. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand invivo. Nat Med 1999, 5:157-163.
25. Kagawa S., He C., Gu J., Koch P., Rha S.J., Roth J.A., et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001, 61:3330-3338.
26. Wang Y., Gao S., Ye W.H., Yoon H.S., Yang Y.Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 2006, 5:791-796.
27. Saad M., Garbuzenko O.B., Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond) 2008, 3:761-776.
28. Chen A.M., Zhang M., Wei D., Stueber D., Taratula O., Minko T., et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009, 5:2673-2677.
29. Kaneshiro T.L., Lu Z.R. Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials 2009, 30:5660-5666.
30. Hu C.-M.J., Aryal S., Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv 2010, 1:323-334.
31. Meng H., Liong M., Xia T., Li Z., Ji Z., Zink J.I., et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010, 4:4539-4550.
32. Zhu C., Jung S., Luo S., Meng F., Zhu X., Park T.G., et al. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials 2010, 31:2408-2416.
33. Sun T.-M., Du J.-Z., Yao Y.-D., Mao C.-Q., Dou S., Huang S.-Y., et al. Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression. ACS Nano 2011, 5:1483-1494.
34. Zhao F., Yin H., Li J. Supramolecular self-assembly forming a multifunctional synergistic system for targeted co-delivery of gene and drug. Biomaterials 2014, 35:1050-1062.
35. Han L., Huang R., Li J., Liu S., Huang S., Jiang C. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer. Biomaterials 2011, 32:1242-1252.
36. Liu S., Guo Y., Huang R., Li J., Huang S., Kuang Y., et al. Gene and doxorubicin co-delivery system for targeting therapy of glioma. Biomaterials 2012, 33:4907-4916.
37. Deng Z.J., Morton S.W., Ben-Akiva E., Dreaden E.C., Shopsowitz K.E., Hammond P.T. Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. ACS Nano 2013, 7:9571-9584.
38. Shau M.D., Shih M.F., Lin C.C., Chuang I.C., Hung W.C., Hennink W.E., et al. Aone-step process in preparation of cationic nanoparticles with poly(lactide-co-glycolide)-containing polyethylenimine gives efficient gene delivery. Eur J Pharm Sci 2012, 46:522-529.
39. Chou T.-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58:621-681.
40. Deng Y., Saucier-Sawyer J.K., Hoimes C.J., Zhang J., Seo Y.-E., Andrejecsk J.W., et al. The effect of hyperbranched polyglycerol coatings on drug delivery using degradable polymer nanoparticles. Biomaterials 2014, 35:6595-6602.
41. Danhier F., Feron O., Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. JControl Release 2010, 148:135-146.
42. Moghimi S.M., Symonds P., Murray J.C., Hunter A.C., Debska G., Szewczyk A. Atwo-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol Ther 2005, 11:990-995.
43. Choi S.-W., Kwon H.-Y., Kim W.-S., Kim J.-H. Thermodynamic parameters on poly(d,l-lactide-co-glycolide) particle size in emulsification-diffusion process. Colloids Surf Physicochem Eng Asp 2002, 201:283-289.
44. Hellwig C.T., Rehm M. TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol Cancer Ther 2012, 11:3-13.
45. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Girard O.M., et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009, 16:510-520.